[go: up one dir, main page]

PE20120400A1 - Contrucciones de casb7439 - Google Patents

Contrucciones de casb7439

Info

Publication number
PE20120400A1
PE20120400A1 PE2011002023A PE2011002023A PE20120400A1 PE 20120400 A1 PE20120400 A1 PE 20120400A1 PE 2011002023 A PE2011002023 A PE 2011002023A PE 2011002023 A PE2011002023 A PE 2011002023A PE 20120400 A1 PE20120400 A1 PE 20120400A1
Authority
PE
Peru
Prior art keywords
seq
casb7439
constructions
construction
lvl168
Prior art date
Application number
PE2011002023A
Other languages
English (en)
Inventor
Normand Blais
Martine Harvey
Anthony Pilorget
Clement Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20120400A1 publication Critical patent/PE20120400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN POLIPEPTIDO CASB7439 MODIFICADO QUE COMPRENDE LA SUPRESION DE PARTE O TODA LA REGION RICA EN PROLINA DE LA SEQ ID NO:13. TAMBIEN ESTA REFERIDA A UNA COMPOSICION INMUNOGENICA, UNA MOLECULA DE ACIDO NUCLEICO Y A UNA CONSTRUCCION DE LA PROTEINA QUE COMPRENDE UNA CONSTRUCCION SELECCIONADA DE: a) LVL055 (SEQ ID NO:1), b) LVL111 (SEQ ID NO:3), c) LVL137 (SEQ ID NO:5), d) LVL141 (SEQ ID NO:7), e) LVL144 (SEQ ID NO:9) Y LVL168 (SEQ ID NO:11)
PE2011002023A 2009-05-27 2010-05-25 Contrucciones de casb7439 PE20120400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US22039609P 2009-06-25 2009-06-25

Publications (1)

Publication Number Publication Date
PE20120400A1 true PE20120400A1 (es) 2012-05-04

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002023A PE20120400A1 (es) 2009-05-27 2010-05-25 Contrucciones de casb7439

Country Status (19)

Country Link
US (1) US8916514B2 (es)
EP (1) EP2435469A1 (es)
JP (1) JP2012528106A (es)
KR (1) KR20120014054A (es)
CN (1) CN102459324B (es)
AU (1) AU2010252012A1 (es)
BR (1) BRPI1012078A2 (es)
CA (1) CA2763486A1 (es)
CL (1) CL2011002994A1 (es)
CO (1) CO6400229A2 (es)
DO (1) DOP2011000348A (es)
EA (1) EA020617B1 (es)
IL (1) IL216351A0 (es)
MA (1) MA33409B1 (es)
MX (1) MX2011012623A (es)
NZ (1) NZ596501A (es)
PE (1) PE20120400A1 (es)
SG (1) SG176220A1 (es)
WO (1) WO2010136443A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
ATE534401T1 (de) * 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
JP7346291B2 (ja) * 2016-09-21 2023-09-19 アマル セラピューティクス エスエー 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3724093A (en) 1992-02-18 1993-09-03 Smithkline Beecham Corporation Vaccinal polypeptides
WO1995014772A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2245545C (en) 1996-02-09 2008-12-30 Smithkline Beecham Biologicals S.A. Vaccines against varicella zoster virus gene 63 product
ATE315088T1 (de) 1998-02-05 2006-02-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
PL343429A1 (en) 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
DK1165778T3 (da) 1999-03-11 2007-02-12 Glaxosmithkline Biolog Sa Anvendelser af CASB618-polynukleotider og -polypeptider
WO2001002828A2 (en) 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
SI1265915T1 (sl) * 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
WO2002061085A2 (en) 2000-10-31 2002-08-08 Ryan James W Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0104259D0 (en) 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
GB0111974D0 (en) 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
EP1575515A4 (en) 2002-08-29 2007-08-08 Genentech Inc ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
US20080108070A1 (en) 2006-09-08 2008-05-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Also Published As

Publication number Publication date
EA020617B1 (ru) 2014-12-30
KR20120014054A (ko) 2012-02-15
CA2763486A1 (en) 2010-12-02
CL2011002994A1 (es) 2012-07-20
IL216351A0 (en) 2012-01-31
EP2435469A1 (en) 2012-04-04
MX2011012623A (es) 2011-12-14
US8916514B2 (en) 2014-12-23
CN102459324B (zh) 2014-07-09
CO6400229A2 (es) 2012-03-15
JP2012528106A (ja) 2012-11-12
MA33409B1 (fr) 2012-07-03
NZ596501A (en) 2013-11-29
EA201190274A1 (ru) 2012-06-29
BRPI1012078A2 (pt) 2019-09-24
US20120070491A1 (en) 2012-03-22
CN102459324A (zh) 2012-05-16
SG176220A1 (en) 2011-12-29
DOP2011000348A (es) 2012-01-15
AU2010252012A1 (en) 2011-12-22
WO2010136443A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
PE20120400A1 (es) Contrucciones de casb7439
EA201000327A1 (ru) Белок
CA3081446A1 (en) Methods and compositions for polypeptide analysis
UA111818C2 (uk) Антитіло проти csf-1r
CU24058B1 (es) Antagonistas de pcsk9
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
NZ601374A (en) Stabilized antibody-containing liquid formulations
EP2493506A4 (en) IL-17A ANTAGONISTS
CO6491076A2 (es) Formulaciones de toxinas botulínica libre de albúmina
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
NZ715038A (en) T cell receptors
MX2014005108A (es) Constructos de polipeptidos y sus usos.
UA118167C2 (uk) Пептид та його застосування
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
UA110806C2 (uk) Мікобактеріальна антигенна композиція
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
ATE404225T1 (de) Radiofluorierte peptide
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
EA200901441A1 (ru) Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90
AR053259A1 (es) Trigo con nuevo almidon y metodo para producirlo
CY1111630T1 (el) Παραγωγα κυτοκινων
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
UA100692C2 (ru) Днк-плазмиды, имеющие повышенную экспрессию и стабильность

Legal Events

Date Code Title Description
FC Refusal